Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9106913 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTL3MBTL1LMNAMEN1 | |
| SCHEMBL28820927 | 0.83 | DGKA (0.50) | ALDH1A1DGKAMAPTNAAAHTR2C | |
| SCHEMBL29549657 | 0.83 | DGKA (0.50) | ALDH1A1MAPK1DGKANAAAHTR2C | |
| SCHEMBL10614340 | 0.81 | DGKA (0.44) | ALDH1A1MAPK1DGKAMAPTRECQL | |
| SCHEMBL27469500 | 0.80 | ALDH1A1 (0.35) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL16814874 | 0.80 | DGKA (0.47) | ALDH1A1DGKAMAPTNAAAHTR2C | |
| SCHEMBL8413450 | 0.79 | MEN1 (0.52) | ALDH1A1DGKAMAPTNAAALMNA | |
| SCHEMBL29549695 | 0.78 | NAAA (0.53) | DGKANAAAHTR2CEPHX2PRKCA | |
| SCHEMBL28594649 | 0.77 | DGKA (0.44) | ALDH1A1DGKAMAPTNAAAHTR2C | |
| SCHEMBL11829329 | 0.77 | NAAA (0.56) | DGKANAAAHTR2CEPHX2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738679-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2646444-B1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | EPIZYME INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160024134-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2014152566-A2 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2012075381-A1 | SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024134-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | ALDH1A1 652/4885MAPK1 1341/4885DGKA 3347/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | ALDH1A1 592/4885MAPK1 918/4885DGKA 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.